CRCI²NA - Nantes - Angers Cancer and Immunology Research Center

Team 1: ITMI

Immunomodulation of the Tumor Microenvironment and Immunotherapy of Thoracic Cancers

Team leaders: Dr Christophe Blanquart & Jean-François Fonteneau

The ITMI team aims at characterizing the tumor microenvironment of thoracic cancers with an emphasis on the non-small cell lung cancer and the malignant pleural mesothelioma, and make this knowledge to develop innovative therapeutic strategies and improve patient management.

Our research is based on a common methodology to all our projects:
-The use of a unique collection of patient-derived cell lines.
-The use of pathological and healthy specimens (pleural fluids, blood, tissues) from mesothelioma or lung cancer patients.


Study of the tumor-associated macrophages (TAMs) in the tumor microenvironment

christophe Christophe Blanquart

On the basis of collections of patient’s samples and derived cell lines, we i) described the function of pleural fluids from malignant pleural mesothelioma (MPM) patients on the formation of immunosuppressive macrophages (Chéné et al, J Thorac Oncol, 2016), ii) demonstrated the involvement of the CSF-1/IL-34/CSF-1R pathway in the formation of these macrophages using 3D models of MPM (Blondy et al, J Immunother Cancer, 2020) and iii) evaluated an approach to reprogram TAM and reduce immunosuppression (Lavy et al, Front Immunol, 2023). The objectives of our works are now i) to characterize at the molecular and functional level subpopulations of TAMs, ii) to identify new factors responsible for the differentiation of monocytes into immunosuppressive macrophages subpopulations and iii) to develop new therapeutic strategies to inhibit/reprogram immunosuppressive macrophages.
Modeling endothelial cell’s (ECs) interactions within the tumor microenvironment

Lucas ok Lucas Treps

Initially thought to act as a passive conduit for oxygen and nutrients to feed the tumor and allowing its metastatic dissemination, ECs are now recognize as active players in the tumor microenvironment. Particularly, we showed ECs to be equipped with immunoregulatory properties and highly heterogeneous by nature. However, so far their precise functions remain uncharacterized, seeking for the development of relevant models. As such, we have built various 2D & 3D in vitro models integrating ECs, macrophages, and cancer-associated fibroblasts to mimic the tumor ecosystem. By combining scRNA-seq, imaging and microfluidic technologies we aim at defining the exact functions, interactions and extracellular communications (e.g. by means of extracellular vesicles) of ECs within the tumor microenvironment. As a strong expertise of our team, we are particularly interested in the monocytic/lymphocytic compartments, and how tumor cell-educated ECs are able to modulate their response.


Remodeling of the endothelial compartment in lung cancer upon therapies: Mechanisms and consequences

Isabelle2 Isabelle Corre

Within the lung tumor microenvironment (TME), we are interested in exploring how endothelial cells (ECs) contribute to the overall tumor response to therapies (chemotherapies, small kinase inhibitors, radiotherapy and immune checkpoint inhibitors). We aim at understanding how therapies may induce a remodeling of the endothelial TME. We are deciphering effects of treatments on i) the biology of ECs (survival, angiogenesis, endothelial-to-mesenchymal transition) and ii) on the endothelial communication with other TME actors, namely cancer-associated fibroblasts CAFs and immune cells (lymphocytes, macrophages). Therefore, we will address the consequences of the endothelial remodeling on tumor progression and cancer cell’s dissemination and response to therapies. Our ultimate goal is to identify key signals of the endothelial compartment response to chemo-/radio-/immunotherapies that could be targeted to limit treatment resistance and ameliorate therapeutic issues in lung cancer.

Non-coding RNAs in response to therapies in lung cancer

del3 Delphine Fradin

We are interested in the impact of treatments on tumor cells, from molecular mechanisms to clinically relevant biomarkers, by focusing on non-coding RNA (ncRNA). Our work has: i) described the role of miRNAs included in small extracellular vesicles (EVs) in tumor immune escape (Vignard et al. Cancer Immunology Research 2020), ii) shown the involvement of miRNAs in radiotherapy resistance (Labbé et al. in revision), and iii) demonstrated the impact of genetic mutations on the ncRNA content of tumor-derived small EVs (Labbé et al. Journal of Extracellular Biology 2023).
Our goals are now to identify, using large scale approaches, such as CRISPR screen and RNA-seq analysis: i) novel lncRNAs involved in treatment resistance and ii) clinically relevant miRNAs as non-invasive prognostic biomarkers.


Development of targeted therapies for Malignant Pleural Mesothelioma (MPM) treatment

christophe Christophe Blanquart

MPM is an aggressive disease characterized by a poor response to current therapies, including immunotherapies. The development of new therapies is usually hampered by the toxicity, the solubility and the biodistribution of molecules. Vectorization appears as an interesting approach to overcome these limits. Thus, our works aim at developing new strategies based i) on the development of nanovectors (Linot et al, ACS Appl Mater Interfaces, 2017), ii) to identify new affinity reagents for the targeted therapies of thoracic cancers (Patent EP23307349.3 (12/22/2023)) and iii) to combine these approaches to obtain specific nanovectors of thoracic cancer cells (Briolay et al, Int J Nanomed, 2024). Our objectives are now to i) to load therapies into targeted nanovectors, ii) to develop new nanovectors derived from viruses, virus-like particles (VLPs) and iii) to extend the exploitation of our affinity reagents to additional targeted therapy approaches.
Sensitivity of tumor cells to oncolytic viruses and induction of immunogenic cell death
jff Jean-François Fonteneau
Antitumor virotherapy consists in the use of oncolytic viruses (OV) that are able to target specifically tumor cells without harming the healthy ones. We study several OVs with a focus on the attenuated strain of measles virus(MV), that is produced by the group of Dr F. Tangy (Institut Pasteur, Paris). We characterized the mechanisms of the antitumor properties of MV against mesothelioma, melanoma, lung and colorectal adenocarcinomas. These studies allow us to develop strategies to increase oncolytic activity of OV against tumor cells. Furthermore, we showed that when infected, these different types of tumor cells undergo immunogenic cell death that allows activation of several antitumor immune populations, for example myeloid and plasmacytoid dendritic cells that are able to activate cytotoxic T cell responses by cross-presenting tumor antigens. With Dr F Tangy, we founded the start-up Oncovita to develop clinical trials using oncolytic MV to treat cancer patients. This clinical trial should start in 2025. The modified MV that will be evaluated in this clinical trial has been patented by F Tangy and us (EP2948157B1, WO2014114605A1, US20150359873A1, 2014).
Modulation of the tumor microenvironment with oncolytic viruses

nicolas Nicolas Boisgerault

In addition to their direct oncolytic activity and their ability to activate different types of immune cells, oncolytic viruses can be used as vectors to deliver therapeutic transgenes to tumors. Using different viral platforms (e.g. Vaccinia, VSV), we created new oncolytic viruses encoding for a diversity of immunomodulating molecules, including chimeric TAME-IT molecules (patent WO2023006975), agonistic antibodies or chemokines. We are now studying the effects of these oncolytic vectors on the different cells types found in the tumor microenvironment with the objective of improving current immunotherapies. We are also interested in understanding how these viruses exploit intercellular communications by extracellular vesicles to transfer molecules between tumor cells and non-malignant cells (Hirigoyen et al., in revision).

Team members


Christophe Blanquart, DR2 (CNRS)
Jean-François Fonteneau, CRCN (INSERM)
Nicolas Boisgerault, CRCN (INSERM)
Isabelle Corre, CRHC (CNRS)
Delphine Fradin, CRCN (INSERM)
Lucas Treps, CRCN (CNRS)

Laurent Cellerin, PH (CHU Nantes)
Anne-Laure Chéné, AHU (CHU Nantes)
Murielle Corvaisier-Chiron, CEC (CHU Nantes)
Marc Denis, PU-PH (CHU Nantes)
Elvire Pons-Tostivint, MCU-PH (CHU Nantes)
Christine Sagan, PH (CHU Nantes)

Tiphaine Delaunay, Post-doctorante
Tacien Petithomme, Post-doctorant

Camille Chatelain, IE (CDD INSERM)
Marine Cotinat, AI (CDD INSERM)
Virginie Dehame, TR (CHU Nantes)
Sophie Deshayes, TR (CNRS)
Judith Fresquet, IE (INSERM)
Joëlle Nader, IE (CDD INSERM)

Clara Bourreau, PhD Student
Manon Chang, PhD Student
Morgane Fouet, PhD Student
Morgane Krejbich, PhD Student
Thomas Papazyan, PhD Student
Hortense Perdrieau, PhD Student
Nikita Rajkumari, PhD Student

About us

ITMI lab

IRSUN - Floor 6
8 quai Moncousu - BP 70721 - 44007 Nantes cedex 1

Selected Publications

Impact of RAFT chain transfer agents on the polymeric shell density of magneto-fluorescent nanoparticles and their cellular uptake.
Blondy T, Poly J, Linot C, Boucard J, Allard-Vannier E, Nedellec S, Hulin P, Hénoumont C, Larbanoix L, Muller RN, Laurent S, Ishow E, Blanquart C.
Nanoscale. 2022 Apr 14;14(15):5884-5898. doi: 10.1039/d1nr06769a.

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma.
Delaunay T, Nader J, Grard M, Farine I, Hedwig V, Foloppe J, Blondy T, Violland M, Pouliquen D, Grégoire M, Boisgerault N, Erbs P, Fonteneau JF.
Mol Ther Oncolytics. 2020 Aug 25;18:573-578. doi: 10.1016/j.omto.2020.08.011. eCollection 2020 Sep 25.PMID: 32995481 Free PMC article.

Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
Blondy T, d'Almeida SM, Briolay T, Tabiasco J, Meiller C, Chéné AL, Cellerin L, Deshayes S, Delneste Y, Fonteneau JF, Boisgerault N, Bennouna J, Grégoire M, Jean D, Blanquart C.
J Immunother Cancer. 2020 Jun;8(1):e000182. doi: 10.1136/jitc-2019-000182.

Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF.
J Thorac Oncol. 2020 May;15(5):827-842. doi: 10.1016/j.jtho.2019.12.128. Epub 2020 Jan 13.

MicroRNAs in Tumor Exosomes Drive Immune Escape in Melanoma.
Vignard V, Labbé M, Marec N, André-Grégoire G, Jouand N, Fonteneau JF, Labarrière N, Fradin D.
Cancer Immunol Res. 2020 Feb;8(2):255-267. doi: 10.1158/2326-6066.CIR-19-0522. Epub 2019 Dec 19.


aviesan janssen
ARC IRSPdL fondation avenir inca canceropole igo ifct

ars meso 44 chu

Publications list

2024 :
  • Briolay T, Fresquet J, Meyer D, Kerfelec B, Chames P, Ishow E, Blanquart C. Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies. Int J Nanomed. 2024. 20;19:633-650

  • Bessonneau-Gaborit V, Cruard J, Guerin-Charbonnel C, Derrien J, Alberge JB, Douillard E, Devic M, Deshayes S, Campion L, Westermann F, Moreau P, Herrmann C, Bourdon J, Magrangeas F, Minvielle S. Exploring the impact of dexamethasone on gene regulation in myeloma cells. Life Sci Alliance. 2023 ;6(9):e202302195. doi: 10.26508/lsa.202302195.
  • Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. Lung Cancer. 2023. 185:107360
  • Labbé M, Menoret E, Letourneur F, Saint-Pierre B, de Beaurepaire L, Veziers J, Dreno B, Denis MG, Blanquart C, Boisgerault N, Fonteneau JF, Fradin D. TP53 mutations correlate with the non-coding RNA content of small extracellular vesicles in melanoma. Journal of Extracellular Biology. 2023. Volume 2, Issue 8. 2:e105.
  • Boisgerault N, Bertrand P. Inside PD-1/PD-L1,2 with their inhibitors. Eur J Med Chem. 2023 Aug 5;256:115465. doi: 10.1016/j.ejmech.2023.115465. Epub 2023 May 6. PMID: 37196547.
  • Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C. ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Front Immunol. 2023 Jul 19;14:1196731. doi: 10.3389/fimmu.2023.1196731. eCollection 2023.
  • Grard M, Idjellidaine M, Arbabian A, Chatelain C, Berland L, Combredet C, Dutoit S, Deshayes S, Dehame V, Labarrière N, Fradin D, Boisgerault N, Blanquart C, Tangy F, Fonteneau JF. Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. Cancer Immunol Immunother. 2023 Jul 19. doi: 10.1007/s00262-023-03486-4. Online ahead of print.PMID: 37466668.
  • Fradin D, Tost J, Busato F, Mille C, Lachaux F, Deleuze JF, Apter G, Benachi A. DNA methylation dynamics during pregnancy. Front Cell Dev Biol. 2023 May 22;11:1185311. doi: 10.3389/fcell.2023.1185311. eCollection 2023.PMID: 37287456.
  • Bourreau C, Treps L, Faure S, Fradin D, Clere N. Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. Pharmacol Ther. 2023 Jan 12:108347. doi: 10.1016/j.pharmthera.2023.108347.
2022 :
  • Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clin Res Rep. 2022 Nov 7;3(12):100430.
  • Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Sallé F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Mol Oncol. 2022 Nov 30. doi: 10.1002/1878-0261.13351.
  • Hariharan A, Qi W, Rehrauer H, Wu L, Ronner M, Wipplinger M, Kresoja-Rakic J, Sun S, Oton-Gonzalez L, Sculco M, Serre-Beinier V, Meiller C, Blanquart C, Fonteneau JF, Vrugt B, Rüschoff JH, Opitz I, Jean D, de Perrot M, Felley-Bosco E. Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment. Mol Oncol. 2022 Oct 11. doi: 10.1002/1878-0261.13322.
  • Mai HL, Deshayes S, Nguyen TV, Dehame V, Chéné AL, Brouard S, Blanquart C. IL-7 is expressed in malignant mesothelioma and has a prognostic value. Mol Oncol. 2022 Aug 28. doi: 10.1002/1878-0261.13310.
  • Autin P, Deshayes S, Lea J, Boisgerault N, Dupré E, Labarrière N, Leguevel R, Fonteneau JF, Blanquart C, Fradin D.The DCMU Herbicide Shapes T-cell Functions By Modulating Micro-RNA Expression Profiles. Front Immunol. 2022 Jul 28;13:925241. doi: 10.3389/fimmu.2022.925241. eCollection 2022.
  • Treps L, Ager A, Hida K. Editorial: Tumor Vessels as Directors of the Tumor Microenvironment: New Findings, Current Challenges & Perspectives. Front Cell Dev Biol. 2022 Mar 29;10:885670. doi: 10.3389/fcell.2022.885670. eCollection 2022.
  • Chaumette T, Cinotti R, Mollé A, Solomon P, Castain L, Fourgeux C, McWilliam HE, Misme-Aucouturier B, Broquet A, Jacqueline C, Vourc'h M, Fradin D, Bossard C, David L, Montassier E, Braudeau C, Josien R, Villadangos JA, Asehnoune K, Bressollette-Bodin C, Poschmann J, Roquilly A. Monocyte Signature Associated with Herpes Simplex Virus Reactivation and Neurological Recovery After Brain Injury.  Am J Respir Crit Care Med. 2022 Apr 29.
  • Mathiot L, Herbreteau G, Robin S, Fenat C, Bennouna J, Blanquart C, Denis M, Pons-Tostivint E. HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. 2022. Curr Oncol. May 20;29(5):3748-3758.
  • Blondy T, Poly J, Linot C, Boucard J, Allard-Vannier E, Nedellec S, Hulin P, Hénoumont C, Larbanoix L, Muller RN, Laurent S, Ishow E and Blanquart C. Impact of RAFT chain transfer agents on the polymeric shell density of magneto-fluorescent nanoparticles and their cellular uptake. 2022. Nanoscale. 14(15):5884-5898.
  • Laquinta S, Khazaie S, Ishow É, Blanquart C, Fréour S, Jacquemin F. Influence of the mechanical and geometrical parameters on the cellular uptake of nanoparticles: a stochastic approach. 2022.  Int J Numer Method Biomed Eng. Mar 27:e3598. doi: 10.1002/cnm.3598.
  • Charrier M, Lorant J, Contreras-Lopez R, Téjédor G, Blanquart C, Lieubeau B, Schleder C, Leroux I, Deshayes S, Fonteneau JF, Babarit C, Hamel A, Magot A, Péréon Y, Viau S, Delorme B, Luz-Crawford P, Lamirault G, Djouad F, Rouger K. Human MuStem cells exert inhibitory function on T-cell proliferation and cytotoxicity through paracrine and contact-dependent pathways. 2022. Stem Cell Res. 10;13(1):7.
  • Marazioti A, Krontira AC, Behrend SJ, Giotopoulou GA, Ntaliarda G, Blanquart C, Bayram H, Iliopoulou M, Vreka M, Trassl L, Pepe MAA, Hackl CM, Klotz LV, Weiss SAI, Koch I, Lindner M, Hatz RA, Behr J, Wagner DE, Papadaki H, Antimisiaris SG, Jean D, Deshayes S, Grégoire M, Kayalar Ö, Mortazavi D, Dilege Ş, Tanju S, Erus S, Yavuz Ö, Bulutay P, Fırat P, Psallidas I, Spella M, Giopanou I, Lilis I, Lamort AS, Stathopoulos GT. KRAS signaling in malignant pleural mesothelioma. 2022. EMBO Mol Med. 13:e13631.
2021 :
  • Pons-Tostivint E, Lugat A, Fontenau JF, Denis MG, Bennouna J. STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.  2021. Cells. 11;10(11):3129.
  • Ollivier L, Labbé M, Fradin D, Potiron V, Supiot S. Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer. 2021. Front Oncol. 11:744679.
  • Ollivier L, Guimas V, Rio E, Vaugier L, Masson I, Libois V, Labbé M, Fradin D, Potiron V, Supiot S. 2021. Combination radiotherapy-immunotherapy in genitourinary cancer. Cancer Radiother. 25(6-7):565-569.
  • Grard M, Chatelain C, Delaunay T, Pons-Tostivint E, Bennouna J, Fonteneau JF. 2021.  Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Front Oncol. 11:695770.
  • Lavy M, Gauttier V, Poirier N, Barillé-Nion S, Blanquart C. 2021. Specialized Pro-Resolving Mediators Mitigate Cancer-Related Inflammation: Role of Tumor-Associated Macrophages and Therapeutic Opportunities. Front Immunol. Jun 30;12:702785.
  • Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. 2021. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer. 20(1):55.
  • Sun S, Frontini F, Qi W, Hariharan A, Ronner M, Wipplinger M, Blanquart C, Rehrauer H, Fonteneau JF, Felley-Bosco E. 2021. Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development. Cancer Lett. 10:S0304-3835(21)00108-7.
  • Tournier P, Guicheux J, Paré A, Maltezeanu A, Blondy T, Veziers J, Vignes C, André M, Lesoeur J, Barbeito A, Bardonnet R, Blanquart C, Corre P, Geoffroy V, Weiss P, Gaudin A. 2021. A partially demineralized allogeneic bone graft: in vitro osteogenic potential and preclinical evaluation in two different intramembranous bone healing models. Sci Rep. Mar 1;11(1):4907.
  • Soamalala J, Diot S, Pellerano M, Blanquart C, Galibert M, Jullian M, Puget K, Morris MC. 2021. Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts. Chembiochem. 22(6):1065-1071.
2020 :
  • Petithomme T, Grard M, Fonteneau JF, Boisgerault N. Le vaccin contre la fièvre jaune : un nouveau traitement anti-tumoral ? Médecine/Sciences. 2020 Dec;36(12):1216-1217.
  • Delaunay T, Nader J, Grard M, Farine I, Hedwig V, Foloppe J, Blondy T, Violland M, Pouliquen D, Grégoire M, Boisgerault N, Erbs P, Fonteneau JF. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma. Molecular Therapy Oncolytics. 2020 Aug 25;18:573-578.
  • Vallion R, Divoux J, Glauzy S, Ronin E, Lombardi Y, Lubrano di Ricco M, Grégoire S, Nemazanyy I, Durand A, Fradin D, Lucas B, Salomon BL. Regulatory T Cell Stability and Migration Are Dependent on mTOR. Journal of Immunology 2020 Oct 1;205(7):1799-1809
  • Labbé M, Hoey C, Ray J, Potiron V, Supiot S, Liu SK, Fradin D. microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer 2020 Mar 23;19(1):63
  • Parrot T, Oger R, Allard M, Desfrançois J, Raingeard de la Blétière D, Coutolleau A, Preisser L, Khammari A, Dréno B, Delneste Y, Guardiola P, Fradin D*, Gervois N*. *co-dernier auteurs. Transcriptomic features of tumour-infiltrating CD4lowCD8high double positive αβ T cells in melanoma. Scientific Reports 2020 Apr 3;10(1):5900
  • Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest. 2020. 130(11):6109-6123.
  • Kara-Terki L, Treps L, Blanquart C, Fradin D. Critical Roles of Tumor Extracellular Vesicles in the Microenvironment of Thoracic Cancers. Int J Mol Sci. 2020. 21(17):E6024.
  • Jean D, Delaunay T, Meiller C, Boisgerault N, Grard M, Caruso S, Blanquart C, Felley-Bosco E, Bennouna J, Tangy F, Grégoire M, Fonteneau JF. Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. J Thorac Oncol. 2020. 15(7):e113-e116.
  • Blondy T, d’Almeida SM, Briolay T, Tabiasco J, Meiller C, Chéné AL, Cellerin L, Deshayes S, Delneste Y, Fonteneau JF, Boisgerault N, Bennouna J, Grégoire M, Jean D, Blanquart C. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma. J Immunother Cancer. 2020. 8(1):e000182.
  • Blanquart C, Jaurand MC, Jean D. The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models. Front Oncol. 2020. 25;10:388
  • Delaunay T, Achard C, Boisgerault N, Grard M, Petithomme T, Chatelain C, Dutoit S, Blanquart C, Royer PJ, Minvielle S, Quetel L, Meiller C, Jean D, Fradin D, Bennouna J, Magnan A, Cellerin L, Tangy F, Grégoire M, Fonteneau JF. Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus. J Thorac Oncol. 2020. 15(5):827-842.
  • Delaunay T, Achard C, Grégoire M, Tangy F, Boisgerault N, Fonteneau JF. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death. Methods Mol Biol. 2020. 2058:127-132.
  • Vignard V, Labbé M, Marec N, André-Grégoire G, Jouand N, Fonteneau JF, Labarrière N, Fradin D. MicroRNAs in Tumor Exosomes Drive Immune Escape in Melanoma. Cancer Immunol Res. 2020. Feb;8(2):255-267.
  • Marotte L, Simon S, Vignard V, Dupré E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Schaffer J, Fradin D, Jarry A, N’Guyen T, Labarrière N. Increased anti-tumor efficacy of Human PD-1 deficient Melanoma-specific Lymphocytes. J ImmunoTher Cancer. 2020. 8(1). pii: e000311.
  • Vanbervliet-Defrance B, Delaunay T, Daunizeau T,  Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M,  Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF,  Lebecque S, Mahtouk K. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. Cancer Letters. 2020. 1;472:29-39.
2019 :
  • Samimi M, Benlalam H, Aumond P, Gaboriaud P, Fradin D, Kervarrec T, Florenceau L, Vignard V, Blom A, Touzé A, Gervois N, Labarriere N. Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma. Cell Immunol. 2019. 344:103961.
  • Guillaume T, Dehame V, Chevallier P, Peterlin P, Garnier A, Grégoire M, Pichinuk E, Rubinstein DB, Wreschner DH. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Exp Hematol. 2019. 70:97-108.
  • Bertrand P*, Blanquart C*, Héroguez V*. The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy. Biomolecules. 2019. 12;9(2).
  • Bouchet S, Linot C, Ruzic D, Agbaba D, Fouchaq B, Roche J, Nikolic K, Blanquart C, Bertrand P. Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Med Chem Lett. 2019. 10(6):863-868.
  • Boucard J, Briolay T, Blondy T, Boujtita M, Nedellec S, Hulin P, Grégoire M, Blanquart C*, Ishow E*. Hybrid Azo-fluorophore Organic Nanoparticles as Emissive Turn-on Probes for Cellular Endocytosis. ACS Appl Mater Interfaces. 2019. 11(36):32808-32814.
  • Autin P, Blanquart C, Fradin D. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers (Basel). 2019. 11(10).
  • Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic metalloenzymes. Curr Med Chem. 2019. 26(15):2748-2785.
2018 :
  • Smeele P, d’Almeida SM, Meiller C, Chéné AL, Liddell C, Cellerin L, Montagne F, Deshayes S, Benziane S, Copin MC, Hofman P, Le Pimpec-Barthes F, Porte H, Scherpereel A, Grégoire M, Jean D and Blanquart C. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. Mol Cancer. 2018. 17(1):148.
  • Lok A, Descamps G, Tessoulin B, Chiron D, Eveillard M, Godon C, Le Bris Y, Vabret A, Bellanger C, Maillet L, Barillé-Nion S, Gregoire M, Fonteneau JF, Le Gouill S, Moreau P, Tangy F, Amiot M, Moreau-Aubry A, Pellat-Deceunynck C. p53 regulates CD46 expression and measles virus infection in myeloma cells. Blood Adv. 2018. 11;2(23):3492-3505.
  • Hladíková K, Partlová S, Koucký V, Bouček J, Fonteneau JF, Zábrodský M, Tachezy R, Grega M, Špíšek R, Fialová A. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1. Oral Oncol. 2018. 82:75-82.
  • Vidakovic M, Marinello J, Lahtela-Kakkonen M, Matulis D, Linkuvienė V, Michel BY, Navakauskienė R, Christodoulou MS, Passarella D, Klimasauskas S, Blanquart C, Cuendet M, Ovadi J, Poulain S, Fontaine-Vive F, Burger A, Martinet N.. New Insights into the Epigenetic Activities of Natural Compounds. OBM Genetics. 2018. 2(3):029.
  • Boucard J, Linot C, Blondy T, Nedellec S, Hulin P, Blanquart C*, Lartigue L, Ishow E*. Small Molecule-Based Fluorescent Organic Nanoassemblies with Strong Hydrogen Bonding Networks for Fine Tuning and Monitoring Drug Delivery in Cancer Cells. Small. 2018. 14(38):e1802307.
  • Vignard V and Fradin D. Non-coding RNAs in Cutaneous Melanoma Development, Progression and Dissemination. OBM Genetics. 2018. 2 (2), p1 10.21926/obm.genet.1802020. Review.
  • Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Clinical Epigenetics. 2018. 10:79.
  • Le Stunff C, Castell AL, Todd N, Mille C, Belot MP, Frament N, Brailly-Tabard S, Benachi A, Fradin D, Bougnères P. Fetal growth is associated with CpG methylation in the P2 promoter of the IGF1 gene. Clin Epigenetics. 2018 Apr 19;10:57.
  • Nader JS, Abadie J, Deshayes S, Boissard A, Blandin S, Blanquart C, Boisgerault N, Coqueret O, Guette C, Grégoire M, Pouliquen DL. Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma. Oncotarget. 2018. 27;9(23):16311-16329.
2017 :
  • Linot C, Poly J, Boucard J, Pouliquen D, Nedellec S, Hulin P, Marec N, Arosio P, Lascialfari A, Guerrini A, Sangregorio C, Lecouvey M, Lartigue L, Blanquart C*, Ishow E*. PEGylated Anionic Magnetofluorescent Nanoassemblies: Impact of Their Interface Structure on Magnetic Resonance Imaging Contrast and Cellular Uptake. ACS Appl Mater Interfaces. 2017. 26;9(16):14242-14257.
  • Ben-Avraham D, Govindaraju DR, Budagov T, Fradin D, Durda P, Liu B, Ott S, Gutman D, Sharvit L, Kaplan R, Bougnères P, Reiner A, Shuldiner AR, Cohen P, Barzilai N, Atzmon G. The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature. Sci Adv. 2017. 16;3(6):e1602025.
  • Fradin D, Boëlle PY, Belot MP, Lachaux F, Tost J, Besse C, Deleuze JF, De Filippo G, Bougnères P. Genome-Wide Methylation Analysis Identifies Specific Epigenetic Marks In Severely Obese Children. Sci Rep. 2017.7;7:46311.
  • Belot MP, Nadéri K, Mille C, Boëlle PY, Benachi A, Bougnères P, Fradin D. Role of DNA methylation at the placental RTL1 gene locus in type 1 diabetes. Pediatr Diabetes. 2017. 18(3):178-187.
  • Boisgerault N, Grégoire M, Fonteneau JF.Viral cancer therapies: are they ready for combination with other immunotherapies?  Future Oncol. 2017. 13(18):1569-1571.
  • Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R. Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. Cancer Immunol Res. 2017. 5(11):1029-1045.
  • Simon T, Pogu J, Rémy S, Brau F, Pogu S, Maquigneau M, Fonteneau JF, Poirier N, Vanhove B, Blancho G, Piaggio E, Anegon I, Blancou P. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers. J Autoimmun. 2017. 81:44-55.
  • Delaunay T, Violland M, Boisgerault N, Dréno B, Labarrière N, Bell JC, et al. Oncolytic viruses sensitize tumor cells for NYESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology. 2017. 26;7(3):e1407897.
  • Allagui F, Achard C, Panterne C, Combredet C, Labarrière N, Dréno B, Elgaaied AB, Pouliquen D, Tangy F, Fonteneau JF, Grégoire M, Boisgerault N. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus. Curr Gene Ther. 2017. 16(6):419-428.
  • Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Grégoire M and Fonteneau JF. Oncolytic measles virus induces Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology. 2017. 26;7(3):e140789
Mis à jour le 10 April 2024.